論文種別	原著(症例報告除く)
言語種別	英語
査読の有無	その他(不明)
表題	Radioimmunotherapy for Malignant Mesothelioma Targeting C-ERC/Mesothelin.
掲載誌名	正式名：Pharmaceuticals (Basel, Switzerland) 略　 称：Pharmaceuticals (Basel) ISSNコード：14248247/14248247
掲載区分	国外
巻・号・頁	19(3),pp.501
著者・共著者	Hirofumi Hanaoka, Aiko Yamaguchi, Masahiro Maeda, Tatsuya Segawa, Noboru Oriuchi
発行年月	2026/03
概要	Background/Objectives: Malignant mesothelioma has a poor prognosis and limited therapeutic options. C-ERC/mesothelin is highly expressed in mesotheliomas and is a potential target for radioimmunotherapy (RIT). This study evaluated the radiolabeled anti-C-ERC/mesothelin antibody mAb 22A31 as a therapeutic agent. Methods: C-ERC/mesothelin expression in mesothelioma cell lines was assessed by Western blotting, and the specific binding of 125I-labeled mAb 22A31 was examined. Biodistribution of 111In-labeled mAb 22A31 was evaluated in a mesothelioma cell line, MSTO-211H tumor-bearing mice. The therapeutic efficacy of 90Y-labeled mAb 22A31 was evaluated in subcutaneous and pleural dissemination models. Results: mAb 22A31 showed specific binding considering the level of C-ERC/mesothelin expression in each mesothelioma cell line. 111In-mAb 22A31 accumulated in tumors with minimal uptake in normal tissues. 90Y-mAb 22A31 significantly delayed the growth of subcutaneous tumors and improved survival in a pleural dissemination model. Conclusions: Radiolabeled mAb 22A31 specifically targeted C-ERC/mesothelin and demonstrated therapeutic efficacy in a mesothelioma xerograph model. Therefore, 90Y-mAb 22A31 is a promising RIT agent and supports the further development of C-ERC/mesothelin-targeted therapy for mesothelioma.
DOI	10.3390/ph19030501
PMID	41901346